The European Partnership for Personalised Medicine, EP PerMed supported by the European Union under Horizon Europe has launched the joint transnational call 2026 “Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases” (CARMEN2026), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field.
EP PerMed is European Partnership dedicated to Personalised Medicine (PM). It supports PM-related R&I, but also facilitates and accelerates all steps so that PM achievements successfully pass through the full value continuum to be implemented in sustainable health systems for the benefit of people and societies.
This call aims to bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field. The overall objectives of the JTC2026 will be to fund research projects in human health on innovative PM strategies for patients with cardiovascular, metabolic or kidney diseases. Research projects may focus on a single disease or explore these conditions in combination.
Proposals should address one or more of the following aspects:
Development and validation of innovative personalised therapeutic approaches for cardiovascular, metabolic or kidney diseases through testing in relevant pre-clinical models (e.g., human cell cultures, organoids, organs-on-chips, disease-specific animal models, or in silico models).
Identification and validation of molecular markers/signatures or cutting-edge technologies (see also point 2 below) to monitor treatment response in patients with cardiovascular, metabolic or kidney diseases in order to tailor treatment pathways. This may include the analysis of the treatment effectiveness or treatment-related (including multi-medication) adverse effects as well as dose optimisation.
Identification and validation of stratifying molecular markers/signatures or stratifying diagnostic technologies for early disease risk prediction and prevention of disease worsening or comorbidities in patients with cardiovascular, metabolic or kidney diseases, thereby delaying the progression to cardiovascular-kidney-metabolic syndrome.
Each consortium must include at least three partners from three different EU Member States or Associated Countries whose funding organisations participate in the EP PerMed CARMEN2026 call.
Applications:
- International Applications are made through EP PerMed Submission Platform.
- National Applications are made through TÜBİTAK Online Application System.
Call Timeline:
Deadline for the first stage of international proposal submission (pre-proposal): 10 February 2026 (14:00, CET)
Deadline for the first stage of national applications: 16 February 2026 (23:59, UTC+3)
Deadline for the-signature (pre-proposal): 16 February 2026 (23:59, UTC+3)
Deadline for the second stage of international proposal submission*: 9 June 2026 (14:00, CEST)
*The deadline for the second stage national application, to be carried out through TÜBİTAK PBS for projects with positive results in the international evaluation of the second stage, will be announced by TÜBİTAK to the relevant parties.
For more information about the call, click here.
